{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:57:14Z","timestamp":1790096234997,"version":"4.0.1"},"reference-count":17,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:p>\n                    This study evaluated the\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    activity of ceftolozane-tazobactam and comparator agents tested against Enterobacteriaceae and\n                    <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>\n                    isolates from hospitalized patients in the United States. Ceftolozane-tazobactam is an antipseudomonal cephalosporin combined with a well-established \u03b2-lactamase inhibitor. A total of 18,960 organisms (15,223 Enterobacteriaceae and 3,737\n                    <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>\n                    ) were consecutively collected from 32 medical centers located in all nine U.S. census divisions from 2013 to 2016. Organisms were tested for susceptibility by broth microdilution. CLSI and EUCAST interpretive criteria were used. Ceftolozane-tazobactam (94.4% susceptible), amikacin (99.0% susceptible), and meropenem (98.0% susceptible) were the most active compounds tested against Enterobacteriaceae. Among the Enterobacteriaceae isolates tested, 1.9% (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    \u2009=\u2009286) were carbapenem-resistant Enterobacteriaceae (CRE) and 9.5% (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    \u2009=\u20091,450) exhibited an extended-spectrum \u03b2-lactamase (ESBL) non-CRE phenotype. Although ceftolozane-tazobactam showed good activity against ESBL non-CRE phenotype strains of Enterobacteriaceae (87.5% susceptible), it lacked useful activity against CRE. Ceftolozane-tazobactam was the most potent \u03b2-lactam agent tested against\n                    <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>\n                    isolates, with 97.3% susceptible. Only colistin was more active, inhibiting 99.5% of isolates. Ceftolozane-tazobactam also maintained good activity against multidrug-resistant\n                    <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>\n                    , with 88.6% susceptible. Ceftolozane-tazobactam was the most active \u03b2-lactam agent tested against\n                    <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic>\n                    and was more active than available cephalosporins and piperacillin-tazobactam against Enterobacteriaceae.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2017.0266","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T11:58:11Z","timestamp":1508241491000},"page":"563-577","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":49,"title":["Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against\n                    <i>Enterobacteriaceae<\/i>\n                    and\n                    <i>Pseudomonas aeruginosa<\/i>\n                    with Various Resistance Patterns Isolated in U.S. Hospitals (2013\u20132016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility"],"prefix":"10.1177","volume":"24","author":[{"given":"Dee","family":"Shortridge","sequence":"first","affiliation":[{"name":"JMI Laboratories"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Pfaller","sequence":"additional","affiliation":[{"name":"JMI Laboratories"},{"name":"University of Iowa College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,6]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1762"},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0924-8579(00)00189-8","article-title":"The millennium bugs\u2014the need for and development of new antibacterials","volume":"16","author":"Bax R.","year":"2000","unstructured":"Bax R., , Mullan N., , and Verhoef J.. 2000. The millennium bugs\u2014the need for and development of new antibacterials. Int. J. Antimicrob. Agents., 16:51\u201359.","journal-title":"Int. J. Antimicrob. Agents."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2015.0220"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1128\/AAC.00540-16","article-title":"Changes in the frequencies of beta-lactamase genes among Enterobacteriaceae isolates in U.S. Hospitals, 2012 to 2014: activity of ceftazidime-avibactam tested against beta-Lactamase-producing isolates","volume":"60","author":"Castanheira M.","year":"2016","unstructured":"Castanheira M., , Mendes R.E., , Jones R.N., , and Sader H.S.. 2016. Changes in the frequencies of beta-lactamase genes among Enterobacteriaceae isolates in U.S. Hospitals, 2012 to 2014: activity of ceftazidime-avibactam tested against beta-Lactamase-producing isolates. Antimicrob. Agents. Chemother., 60:4770\u20134777.","journal-title":"Antimicrob. Agents. Chemother."},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/joim.12342","article-title":"Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control","volume":"277","author":"Tangden T.","year":"2015","unstructured":"Tangden T., , and Giske C.G.. 2015. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J. Intern. Med., 277:501\u2013512.","journal-title":"J. Intern. Med."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01737-10"},{"key":"e_1_3_3_9_2","unstructured":"ZERBAXA. 2016. ZERBAXA\u00ae (Ceftolozane\/Tazobactam). Merck & Co. Inc. Whitehouse Station NJ."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01802-13"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.04.004"},{"key":"e_1_3_3_12_2","unstructured":"CLSI. 2015. M07\u2013A10. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard\u2014Tenth Edition. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_3_13_2","unstructured":"CLSI. 2017. M100\u2013S127. Performance Standards for Antimicrobial Susceptibility Testing: 27th Informational Supplement. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_3_14_2","unstructured":"EUCAST (2017). Breakpoint tables for interpretation of MIC's and zone diameters. Version 7.1 March 2017. Available at www.eucast.org\/clinical_breakpoints\/ accessed October3 2017."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ijantimicag.2014.01.032","article-title":"Ceftolozane\/tazobactam activity tested against gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European medical centres (2012)","volume":"43","author":"Farrell D.J.","year":"2014","unstructured":"Farrell D.J., , Sader H.S., , Flamm R.K., , and Jones R.N.. 2014. Ceftolozane\/tazobactam activity tested against gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European medical centres (2012). Int. J. Antimicrob. Agents., 43:533\u2013539.","journal-title":"Int. J. Antimicrob. Agents."},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011\u20132012)","volume":"69","author":"Sader H.S.","year":"2014","unstructured":"Sader H.S., , Farrell D.J., , Castanheira M., , Flamm R.K., , and Jones R.N.. 2014. Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011\u20132012). J. Antimicrob. Chemother., 69:2713\u20132722.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw374"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2017.0266","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2017.0266","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2017.0266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:32:24Z","timestamp":1777667544000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2017.0266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1089\/mdr.2017.0266"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2017.0266","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}